US-based Miromatrix Medical has announced a spin-off of its medical device arm Reprise Biomedical following a $12.5m private placement.
Reprise Biomedical commercialises biological medical devices manufactured using perfusion decellularization technology, a process used on a variety of donor organs and tissues to allows the generation of clinical-scale ECM scaffolds with preserved architecture and an intact vascular template.
Following the spin-off, Reprise Biomedical’s portfolio consists of Miromesh and Miroderm, both of which hold the US Food and Drug Administration (FDA) 510(k) clearance and are commercially available.
Miromesh is a biological mesh made using perfusion decelluarized porcine liver for hernia repair applications. It is designed to be implanted to boost soft tissue.
Also derived from decellularized porcine liver, Miroderm is meant for wound management, including diabetic foot ulcers, venous ulcers, pressure ulcers, and surgical and trauma wounds.
Miromesh and Miroderm together recorded $1.75m in net sales last year.
Miromatrix Medical transferred all acellular medical devices in development to Reprise Biomedical. The company intends to continue the development of transplantable organs aimed at addressing the chronic organ shortage.
Medical device firm Vascular Solutions’ former senior marketing vice-president Carrie Powers lead the new spin-off firm. With a portfolio of more than 100 medical devices, Vascular Solutions was sold to Teleflex for $1bn in 2017.